Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: A review

International Psychogeriatrics

Volumn 24, Issue 5, 2012, Pages 689-697

  Thompson, P A ^a   Wright, D E ^a   Counsell, C E ^b   Zajicek, J ^c  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alzheimer's disease; clinical trials; outcome measures; statistical analysis; surrogate markers

Indexed keywords

ABERRANT MOTOR ACTIVITY; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANXIETY; APATHY; BEHAVIOR DISORDER; BIOCHEMISTRY; BLOOD SAMPLING; CAREGIVER BURDEN; CEREBROSPINAL FLUID CULTURE; CLASSIFICATION; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; COGNITION; COMPREHENSION; DAILY LIFE ACTIVITY; DECISION MAKING; DELUSION; DEPRESSION; DISABILITY; DISINHIBITION; DYSPHORIA; EUPHORIA; FOLLOW UP; HALLUCINATION; HUMAN; INFORMATION RETRIEVAL; INTERVENTION STUDY; IRRITABILITY; LINEAR REGRESSION ANALYSIS; MEDLINE; MEMORY; METHODOLOGY; MULTIVARIATE ANALYSIS OF VARIANCE; NEUROIMAGING; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PEER REVIEW; PHYSICAL CAPACITY; REVIEW; SLEEP PATTERN; STATISTICAL ANALYSIS; STUDENT T TEST; URINALYSIS;

AGED; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; HUMANS; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859135159     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610211001116     Document Type: Review

References (20)

1. Apostolova, L. G. et al. (2006). 3D mapping of Mini-Mental State Examination performance in clinical and preclinical Alzheimer's disease. Alzheimer Disease and Associated Disorders, 20, 224-231. (Pubitemid 44900935)
2. Craig-Schapiro, R., Fagan, A. M. and Holtzman, D. M. (2009). Biomarkers of Alzheimer's disease. Neurobiology of Disease, 35, 128-140.
3. Dubois, B. et al. (2010). Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurology, 9, 1118-1127.
4. Fox, N. C., Scahill, R. I., Crum, W. R. and Rosser, M. N. (1999). Correlation between rates of brain atropy and cognitive decline in AD. Neurology, 52, 1687.
5. Hampel, H., Bürgerb, K., Teipel, S. J., Bokdea, A. L. W., Zetterberg, H. and Blennow, K. (2008). Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia, 4, 38-48.
6. Hanyu, H. M., Sakurai, H., Iwamoto, T., Takaski, M., Shindo, H., and Abe, K. (1998). Diffusion weighted MR imaging of hippocampus and temporal white matter in Alzheimer's disease. Journal of Neurological Sciences, 156, 195-200. (Pubitemid 28186474)
7. Higgins, J. P. T. and Green, S. (eds.) (2008). Cochrane Handbook for Systematic Reviews of Interventions (Version 5.0.1), The Cochrane Collaboration, available from www.cochrane-handbook.org.
8. Hobart, J., Posner, H., Aisen, P., Selnes, O., Stern, Y., Thomas, R., Weiner, M. and Zajicek, J. (2009). The ADAS-Cog's performance as a measure: lessons from the ADNI study: Part 3 - Do the scale modifications add value? Alzheimer's and Dementia, 5 (Suppl.), 256.
9. Mendiondo, M., Wesson Ashford, J., Kryscio, R. J. and Schmitt, F. A. (2000). Modelling Mini-Mental State Examination changes in Alzheimer's disease. Statistics in Medicine, 19, 1607-1616.
10. Moher, D. et al. (2010). CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ, 340, 869.
11. Molnar, F. J., Man-Son-Hing, M. and Fergusson, D. (2009). Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society, 57, 536-546.
12. Nestor, P. J., Scheltens, P. and Hodges, J. R. (2004). Advances in early detection of Alzheimer's disease. Nature Reviews: Neuroscience, 5, S34-S41.
13. Pocock, S. J., Geller, N. L. and Tsiatis, A. A. (1987). The analysis of multiple endpoints in clinical trials. Biometrics, 43, 487-498.
14. Rencher, A. C. (2002). Methods of Multivariate Analysis, New York: Wiley Interscience.
15. Skrondal, A. and Rabe-Hesketh, S. (2004). Generalized Latent Variable Modeling: Multilevel, Longitudinal and Structural Equation Models. London: Chapman and Hall/CRC.
16. Tang, D., Geller, N. L. and Pocock, S. J. (1993). On the design and analysis of randomised clinical trials with multiple endpoints. Biometrics, 49, 23-30. (Pubitemid 23175700)
17. Upton, G. and Cook, I. (2008). Oxford Dictionary of Statistics (2nd edn). Oxford: Oxford University Press.
18. Wolfson, C., Moride, Y., Perrault, A., Momoli, F., Demers, L. and Oremus, M. (2000). Drug Treatments for Alzheimer's Disease II. A Review of Outcome Measures in Clinical Trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
19. Woodford, H. J. and George, J. (2007). Cognitive assessment in the elderly: a review of clinical methods. QJM: An International Journal of Medicine, 100, 469-484. (Pubitemid 47241914)
20. Zhang, J., Quan, H., Ng, J. and Stepanavage, M. E. (1997). Some statistical methods for multiple endpoints in clinical trials. Controlled Clinical Trials, 18, 204-221.